Dynavax Technologies (DVAX) -33% premarket after the FDA rejects its hepatitis B vaccine...

|About: Dynavax Technologies Co... (DVAX)|By:, SA News Editor

Dynavax Technologies (DVAX) -33% premarket after the FDA rejects its hepatitis B vaccine Heplisav, citing the need for additional safety data in healthy adults. DVAX says it's confident it can meet the request for more information, but it may also fast-track a refiling by first seeking approval for sick patients.